Ignite Creation Date:
2025-12-25 @ 3:08 AM
Ignite Modification Date:
2025-12-31 @ 11:51 PM
Study NCT ID:
NCT00114933
Status:
COMPLETED
Last Update Posted:
2008-03-21
First Post:
2005-06-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Sponsor:
Arribas, Jose R., M.D.
Organization:
Study Overview
Official Title:
Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy. Lopinavir/ritonavir pharmacokinetics might prevent resistance development in patients who experience virological rebound after single-drug simplification.
Detailed Description:
Primary Study Objective: Efficacy and durability of switching to lopinavir/ritonavir single-drug HAART compared to maintaining therapy based on lopinavir/ritonavir and two nucleosides
Secondary Study Objective(s):
* Safety (related drug AEs/SAEs and laboratory anomalies G3/4) through 48 w.
* Resistance profile on patients with sustained virological failure
* QOL comparing stopping nucleosides versus continuing therapy
* Pharmaco-economic analysis comparing treatment cost between the 2 study arms.
* Predicting factors of failure in the stopping nucleosides arm
Subject Population: 200 patients
Study Design:
RANDOMIZATION:
Patients are randomized (1:1) either to continue under the same treatment or stop nucleosides as follows:
* Stopping nucleosides arm: Lopinavir/r alone.
* Continuing arm: Lopinavir/r + 2 NRTIs
STUDY PROCEDURES: A baseline HIV-RNA, CD4 and routine labs will be collected if the most recent results are not collected within the 4 weeks prior entering the study. Patients will be followed for HIV-RNA (and CD4) at w1, w4, w8, w16, w24, w 36 and w48. After w48, durability of response to lopinavir/r single-drug therapy will be studied long-term (up to w96). Routine hematology and clinical chemistry (including fasting triglycerides and cholesterol, total and HDL/LDL ratio) will be measured at w4, w16, w24, w 36 and w48. A central laboratory will be used for HIV-RNA determinations and to archive plasma/cell samples for further genotype test in case of rebound.
Treatment adherence will be followed with a self-patient report questionnaire (GEEMA study)
All AEs will be collected if suspected relation (possible or probable) to any concomitant ARV drug, and SAEs, related or not, reported within 24h.
Secondary Study Objective(s):
* Safety (related drug AEs/SAEs and laboratory anomalies G3/4) through 48 w.
* Resistance profile on patients with sustained virological failure
* QOL comparing stopping nucleosides versus continuing therapy
* Pharmaco-economic analysis comparing treatment cost between the 2 study arms.
* Predicting factors of failure in the stopping nucleosides arm
Subject Population: 200 patients
Study Design:
RANDOMIZATION:
Patients are randomized (1:1) either to continue under the same treatment or stop nucleosides as follows:
* Stopping nucleosides arm: Lopinavir/r alone.
* Continuing arm: Lopinavir/r + 2 NRTIs
STUDY PROCEDURES: A baseline HIV-RNA, CD4 and routine labs will be collected if the most recent results are not collected within the 4 weeks prior entering the study. Patients will be followed for HIV-RNA (and CD4) at w1, w4, w8, w16, w24, w 36 and w48. After w48, durability of response to lopinavir/r single-drug therapy will be studied long-term (up to w96). Routine hematology and clinical chemistry (including fasting triglycerides and cholesterol, total and HDL/LDL ratio) will be measured at w4, w16, w24, w 36 and w48. A central laboratory will be used for HIV-RNA determinations and to archive plasma/cell samples for further genotype test in case of rebound.
Treatment adherence will be followed with a self-patient report questionnaire (GEEMA study)
All AEs will be collected if suspected relation (possible or probable) to any concomitant ARV drug, and SAEs, related or not, reported within 24h.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| EudraCT 2004-001323-37 | None | None | View |